CRNX Crinetics Pharmaceuticals, Inc.: Accounting Value per Share

Graphic logo of Crinetics Pharmaceuticals (CRNX)

Investing in Crinetics Pharmaceuticals (CRNX) carries the risk of failed final drug trials and stringent regulatory oversight. Crinetics Pharmaceuticals (CRNX) focuses on developing oral tablet formulations for endocrinology to replace costly injections. This daily price chart on GURU.Markets reflects the asset's price action, which currently stands at 11.37, while the business remains unprofitable and relies entirely on investor capital.

Crinetics Pharmaceuticals, Inc. (CRNX): Share Book Value from 07/04/2022 to 09/12/2026

crinetics.com - analytical breakdowns and key metrics (CRNX)

- price and consensus price forecast:
Price Chart Crinetics Pharma|CRNX - Broker Consensus Forecast
- market capitalization data:
Market Valuation Crinetics Pharmaceuticals|CRNX - Business Value
- book capitalization data:
Net Assets per Single Share Crinetics|CRNX - Net Asset Value|Market Capitalization to Book Value Ratio crinetics.com|CRNX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Capital|Short-Term Debt to Equity Crinetics|CRNX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Crinetics Pharmaceuticals|CRNX - Company Long-Term Liabilities|Company Short-Term Debts Crinetics
Fundamental company valuation:Crinetics Pharma - CRNX
Manufactured products of Crinetics

Book value per share determines the portion of equity attributable to a single security. The trend in book value per share reflects the rate of net asset accumulation. This metric is calculated by dividing total equity minus liabilities by the number of shares outstanding. For Crinetics Pharmaceuticals (CRNX), this confirms financial stability despite the absence of proprietary manufacturing plants. The diversification of contract manufacturing minimizes capital expenditures, optimizing the balance sheet structure.

Competitors of Crinetics Pharmaceuticals (CRNX)

Ascendis Pharma Inc. (ASND) - Net Assets per Single Share|Madrigal Corp (MDGL) - Equity per Share|Accounting Value per Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share NewAmsterdam Pharma Corp (NAMS)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS